920.09 CH

TO A LOCAL DESCRIPTION OF THE PROPERTY OF THE					Attorney's Docket No:				
FEE AUTHORIZATION / AMENDMENT TRANSMITTAL LETTER							451F		
Serial No.		Filing Dat		Examiner Pagina	M	Group Art	Unit 1645		
09/21	. 7	-67	mber 14, 1998	DeBerry, Regina	IVI.	L	工	_	
In Re Application of William J. Bo	vie MAY 2 0 20	102					유 유	MA	
For	T.	i i					3	22	
Osteoprotege	erin Bioding Proteins						<del></del>		
TO THE ASSISTANT COMMISSIONER FOR PATENTS:							2002		
Applicant(s) request(s) the following extension of time under 37 CFR 1.136(a):							, 2		
In Re Application of William J. Boyles MAY 2 0 2002  For Osteoprotegerin Broding Proteins  TO THE ASSISTANT COMMISSIONER FOR PATENTS:  Applicant(s) request(s) the following extension of time under 37 CFR 1.136(a):  One month of original due date (\$110.00)  Two months of original due date (\$400.00)									
<ul><li>☐ Two months of original due date (\$400.00)</li><li>☐ Three months of original due date (\$920.00)</li></ul>									
☐ Foui	= - (A 440 00)								
Five months of original due date (\$1,960.00)									
⊠ is filed herewith.									
☐ has been filed.									
The response is the filing of a continuing prosecution application, the prior application having an express									
aba	abandonment conditioned on the granting of a filing date to the continuing application.  The accompanying papers include amended claims for which no additional fee is required.								
							ws:		
The accompanying papers include amended claims the fee for which has been calculated as follows:  CLAIMS AS AMENDED									
(1)	(0)	(2)	(4)	(5)	<del>                                     </del>	(6)		(7)	
(1)	(2) Claims remaining	(3)	(4) Highest number	No. of Extra		(0)		itional	
	After amendment		Previously paid fo	r claims present		Rate		ee	
Total Claims	*	Minus	** =	0	X	\$18	= \$		
Indep. Claims	*	Minus	***	0	X	\$84 \$280	= =	0.00	
1   Filst Appearance of a multiple dependent oldin						\$0.00			
If the entry in c	If the entry in column 2 is less than the entry in column 4, write "0" in column 5.								
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.									
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.  The "Highest No. Previously Paid For" (Total or Indep.) is the highest number found in the appropriate									
box in Col 1. of a prior amendment or the number of claims originally filed.									
☐ The following other fees are incurred by the accompanying papers.									
Other:									
Please charge Deposit Account No. 01-0519 in the name of Amgen Inc. in the amount of \$ 920.00. A duplicate copy of									
this petition is attached.  If an additional extension of time is required, please consider this a request therefore.									
— The second is the second to short and additional face which may be required by the									
accompanying papers, or credit any overpayment to Deposit Account No. 01-0519.									
Please Send Future Correspondence To:									
US Patent Operations/RBW									
Dept. 4300, M/S 27-4-A Robert B. Winter									
AMGEN INC.  One Amgen Center Drive  Attorney/Agent for Applicant(s)  Registration No.: 34,458									
Thousand Oaks, California 91320-1799 Phone: (805) 447-2425									
Date: May 20, 2002									

# **EXPRESS MAIL CERTIFICATE**

"Express Mail" mail labeling number:	EL360693979US	Date of Deposit:	May 20, 2002
I hereby certify that this paper or fee is be above and is addressed to Box AF, Assi	stant Commissioner for Patents, Washington, D.C. 20231	ress Mail Post Office t	to Addressee" service gnder 37 C.F.R. 1.10 on the date indicate
	Printed Name		Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ICE MAY 2 3 2002 TECH CENTER 1600/2900

1647

Group Art Unit No.:

Examiner: DeBerry, Regina M.

Applicant(s):

William J. Boyle

Serial No.:

09/211,297

Filed:

December 14, 1998

For:

Osteoprotegerin Binding Proteins

Docket No.:

A-451F

**RESPONSE** 

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

This is in response to the Office Action dated November 19, 2001 in which Claims 37-57 are rejected under 35 U.S.C. 112, first paragraph. Reconsideration and withdrawal of the rejections are requested.

#### REMARKS

### Examiner correction under 37 CFR 1.126

Applicant acknowledges that Claims 37-47 added in Paper No. 3 dated March 25, 1999 and Claims 48-58 added in Paper No. 8 were renumbered accordingly by the Examiner in view of Applicant's inadvertent omission of Claim 43. Claims 37-57 are currently under examination.

# Rejections under 35 U.S.C. 112

Claims 37-57 are rejected under 35 U.S.C. 112, first paragraph, as the specification allegedly fails to enable the claimed composition wherein the recited OPGbp comprises variants. The Examiner argues that it would require undue experimentation to generate OPGbp variants to which the claimed antibody compositions would bind. Applicants disagree.

Various criteria for determining whether experimentation is undue is set forth in In re Wands 8 USPQ 2d 1400 (Fed. Cir. 1988). In view of the Wands factors, Applicant maintains that the teachings of the

# **EXPRESS MAIL CERTIFICATE**

"Express Mail" mail labeling number: EL360693979US

Date of Deposit:

hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressed ssed to Box AF, Assistant Commissioner for Patents, Washington, D.C. 20231